Researchers at the Swedish Institute of Space Physics (IRF) in Uppsala now have an answer to one of the questions about how this actually occurs.

These computer systems supply rapidly growing data volumes. Computer science now faces the challenge of processing these huge amounts of data (big data) in a…

During the production process, these parts are transferred in between many process steps. Each pick-up and release with conventional gripping systems involves…

One of the biggest riddles in physics is the apparent imbalance between matter and antimatter in our universe. To date, there is no explanation as to why…

Of course, if you’re flying in the vicinity of a black hole, a bit of extra bumpiness is the least of your worries. But it’s still surprising. The accepted…

They have made what's believed to be the first polariton laser that is fueled by electrical current as opposed to light, and also works at room temperature,…

As more people use smart phones or tablets to pay bills, make purchases, store personal information and even control access to their houses, the need for…

However, other forces which are usually considered to be weaker are also at work near these objects. These include forces exerted by the pressure of the…

In a discovery decades in the making, scientists have detected the first of a “theoretical” class of stars first proposed in 1975 by physicist Kip Thorne and…

Neutrinos are tiny, neutral elementary particles that, contrary to the standard model of physics, have been proven to have mass. One possible explanation for…

Intense light from the enormous explosion of a star more than 12 billion years ago — shortly after the Big Bang — recently reached Earth and was visible in the…

Sometimes quantum particles behave like waves. This phenomenon is often used for high precision measurements, for instance in atomic clocks. Usually, only the…

The expression and production of recombinant proteins in bacteria, such as E. coli is a long standing and well known procedure. However, expression in bacterial systems is limited due to cytoplasmic accumulation of the protein of interest (POI). Even though, various attempts have been made to prevent the accumulation of the desired protein in inclusion bodies, there is still no satisfactory solution available to overcome this problem. The present invention enables the expression of POI on the cell surface of bacteria, thereby preventing the cytoplasmic and periplasmic accumulation.

Aptamers are short, single-stranded DNA molecules that can specifically bind proteins due to their three-dimensional structure.
Because of their ability to deactivate different protein functions inside the cell, aptamers are already used successfully in the field of medical diagnosis, as therapeutic agents and in environmental analytics.
So far the technical production of single stranded DNA (ssDNA) within the range of more than 60 n has been linked to a grand
percentage of abbreviated respectively functionless by-products. Bigger aptamers with even 100 n or more have only been
practicable facing great loss of quantity of material. Within the case of aptamers, an exact sequence identity is essential for
technical application, though.
By use of the described technology it is now possible to produce aptamers in the range of 100 n and beyond in unmatched quality and quantity via a multi-copy-fragment (“AptaGENE”), using a combination of both in vitro and in vivo techniques.
[Reference UKL221]

There are no basic technologies for nano-particles available, which are suitable for medical application. The present invention offers such a new technology, which is deal-ing with a bifid copolypeptide consisting of one hydrophilic polysarcosine and one hy-drophobic polycysteine part. The hydrophilic polysarcosine part prevents an unspecific binding on proteins, increases the solubility in the serum, and no immune reaction will be activated. Thus it is an ideal protection for encapsulated drugs.
The polycysteine part forms autonomous micelles in polar solvents, which are stabi-lized by cross linked disulphide bridges. The resulting micelles are stable in blood, in the cytosol, against glutathione and also survive endocytosis of antigen presenting cells or macrophages.
When the disulfide bonds were cleaved by metabolization, the copolymer loses its sta-bility and the active ingredient will be re-leased.

[Reference UMZ314]

Cancer is still the main cause of death despite
the development of many treatment
strategies, including extensive radiation and
chemotherapy. Clinical and research results
from animal test have shown that, besides
viruses, bacteria and parasites, the T-cell
system can also recognize malignant abnormal
cells and is able to destroy those.
Especially CD8+ T-cells (cytotoxic T lymphocytes,
CTLs) can cause responses of
tumor repulsion by the recognition of antigens
that are presented on the cell surface
by Major Histocompatibility Complex Class I
molecules (MHC, in humans HLA Class I).
This invention offers the application of HLAindependent
recognition of tumorassociated
antigens for diagnosis, therapy
and prevention of melanoma and other tumor
types. Two antigens are presented that
can be recognized by CTLs independently
of HLA and whose application in cancer
immune therapy will unlock new therapy
alternatives.
[Reference HMZ077]